UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 24 February 2025, London UK
GSK completes acquisition of IDRx, Inc.
GSK plc (LSE/NYSE: GSK) today announced that it has completed the
acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage
biopharmaceutical company dedicated to developing precision
therapeutics for the treatment of gastrointestinal stromal tumours
(GIST).
As announced previously1,
the acquisition includes lead molecule IDRX-42, an investigational,
highly selective tyrosine kinase inhibitor (TKI) that is designed
to improve outcomes for patients with GIST. IDRX-42 has
demonstrated activity against all clinically relevant primary and
secondary KIT mutations, a key medical need in current GIST
treatment. GIST typically presents in the gastrointestinal (GI)
tract with 80% of cases driven by mutations in the KIT gene that
lead to the growth, proliferation, and survival of tumour cells
(primary or activating mutations).2 90%
of patients treated in the first line develop new KIT mutations
(secondary or resistance mutations) that typically lead to relapse
with limited therapeutic options.3
Hesham Abdullah, Senior Vice President, Global Head Oncology
R&D, GSK, said: "This
acquisition adds to GSK's growing pipeline of targeted therapeutics
for cancers originating in the gastrointestinal tract. We plan to
advance IDRX-42 for second line treatment of gastrointestinal
stromal tumours, where there are no approved treatments to
effectively address all resistance mutations, and accelerate
development in an earlier setting."
Financial Considerations
The total cash consideration for this acquisition amounts to up to
$1.15 billion. This includes an upfront payment of $1 billion, with
the possibility of an additional $150 million milestone payment
contingent upon success-based regulatory approval. GSK will also be
responsible for success-based milestone payments as well as tiered
royalties for IDRX-42 owed to Merck KGaA, Darmstadt,
Germany.
About GIST
GIST represent the most prevalent form of soft tissue sarcoma, with
an estimated annual global diagnosis of 80,000 to 120,000
patients.4 GIST
commonly manifests in the GI tract, with approximately 80% of cases
being attributed to mutations in the KIT gene.5 These
mutations, known as primary or activating mutations in exons 9 and
11, drive the growth, proliferation, and survival of tumour cells.
In the first line of treatment, around 90% of patients develop
secondary or resistance mutations in exons 13 and 17 of the KIT
gene, leading to relapse with limited therapeutic
alternatives.6 Notably,
there are currently no approved TKIs capable of effectively
targeting the full range of clinically significant primary and
secondary mutations in KIT.
About IDRX-42
IDRX-42 is a highly selective, investigational small molecule TKI
designed to target all key KIT mutations in GIST. The U.S. Food and
Drug Administration (FDA) has granted IDRX-42 Fast Track
designation for the treatment of patients with GIST after disease
progression on or intolerance to imatinib, and Orphan Drug
designations for the treatment of GIST.
About IDRx
IDRx is a clinical-stage biopharmaceutical company dedicated to
transforming cancer care with intelligently designed precision
therapies. IDRx aims to address the limitations of today's
precision cancer medicines with highly potent and selective
targeted therapies to stop key tumour escape mechanisms and prolong
response to therapy.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK
enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Annabel
Brownrigg-Gleeson
|
+44 (0)
7901 101944
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Camilla
Campbell
|
+44 (0)
7803 050238
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q4 Results for 2024.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
References
1 GSK
enters agreement to acquire IDRx, Inc. -
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-idrx-inc/
2 Bauer S,
George S, von Mehren M, Heinrich MC. Early and Next-Generation
KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for
Advanced
Gastrointestinal
Stromal Tumor. Front Oncol. 2021 Jul 12;11:672500.
3
Zhou S, Abdihamid O, Tan F, Zhou H, Liu H, Li Z, Xiao S, Li B. KIT
mutations and expression: current knowledge and new insights for
overcoming IM resistance in GIST. Cell Commun Signal. 2024 Feb
27;22(1):153
4
Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova
A, Bulusu VR. Global epidemiology of gastrointestinal stromal
tumours (GIST): A systematic review of population-based cohort
studies. Cancer Epidemiol. 2016 Feb;40:39-46.
5 Bauer
S, George S, von Mehren M, Heinrich MC. Early and Next-Generation
KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for
Advanced
Gastrointestinal
Stromal Tumor. Front Oncol. 2021 Jul 12;11:672500.
6 Zhou
S, Abdihamid O, Tan F, Zhou H, Liu H, Li Z, Xiao S, Li B. KIT
mutations and expression: current knowledge and new insights for
overcoming IM resistance in GIST. Cell Commun Signal. 2024 Feb
27;22(1):153
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
24, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jan 2025 to Feb 2025
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Feb 2024 to Feb 2025
